Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
You may also be interested in...
Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma
Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.
Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma
Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space